Evidence map›Paper›PMID 33923711›Full record

ArticleInternational journal of molecular sciences2021

Antarctic

Kattia Núñez-Montero, Rodrigo Salazar, Andrés Santos, Olman Gómez-Espinoza, Scandar Farah, Claudia Troncoso, Catalina Hoffmann, Damaris Melivilu, Felipe Scott, Leticia Barrientos Díaz

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Kattia Núñez-MonteroLaboratory of Molecular Applied Biology, Center of Excellence in Translational Medicine, Universidad de La Frontera, Avenida Alemania 0458, Temuco 4810296, Chile.
Rodrigo SalazarLaboratory of Molecular Applied Biology, Center of Excellence in Translational Medicine, Universidad de La Frontera, Avenida Alemania 0458, Temuco 4810296, Chile.
Andrés SantosLaboratory of Molecular Applied Biology, Center of Excellence in Translational Medicine, Universidad de La Frontera, Avenida Alemania 0458, Temuco 4810296, Chile.
Olman Gómez-EspinozaBiotechnology Investigation Center, Department of Biology, Instituto Tecnológico de Costa Rica, Cartago 159-7050, Costa Rica.ORCID 0000-0002-8878-078X
Scandar FarahLaboratory of Molecular Applied Biology, Center of Excellence in Translational Medicine, Universidad de La Frontera, Avenida Alemania 0458, Temuco 4810296, Chile.ORCID 0000-0002-1377-2355
Claudia TroncosoLaboratory of Molecular Applied Biology, Center of Excellence in Translational Medicine, Universidad de La Frontera, Avenida Alemania 0458, Temuco 4810296, Chile.ORCID 0000-0001-9019-5574
Catalina HoffmannLaboratory of Molecular Applied Biology, Center of Excellence in Translational Medicine, Universidad de La Frontera, Avenida Alemania 0458, Temuco 4810296, Chile.
Damaris MeliviluLaboratory of Molecular Applied Biology, Center of Excellence in Translational Medicine, Universidad de La Frontera, Avenida Alemania 0458, Temuco 4810296, Chile.
Felipe ScottGreen Technology Research Group, Facultad de Ingenieria y Ciencias Aplicadas, Universidad de los Andes, Santiago 7620001, Chile.
Leticia Barrientos DíazLaboratory of Molecular Applied Biology, Center of Excellence in Translational Medicine, Universidad de La Frontera, Avenida Alemania 0458, Temuco 4810296, Chile.ORCID 0000-0002-5344-054X
Universidad de La Frontera · CLUniversidad de Los Andes, Chile · CL

Funding

ANID (NATIONAL INVESTIGATION AND DEVELOPMENT AGENCY, CHILE) CONICYT‒PFCHA/Doctorado Nacional/2017‒21170263 for K.N-M and CONICYT‒PFCHA/Doctorado Nacional/ 2017‒21171392INSTITUTO ANTÁRTICO CHILENO (INACH) INACH RT_14‒12 and INACH DG_01-19NETWORK FOR EXTREME ENVIRONMENTS RESEARCH (NEXER) NXR17-0003UFRO/UANDES INI4UNIVERSIDAD DE LA FRONTERA DI19-0079
6 · The paper itself

Abstract

There has been a recent increase in the exploration of cold-active β-galactosidases, as it offers new alternatives for the dairy industry, mainly in response to the current needs of lactose-intolerant consumers. Since extremophilic microbial compounds might have unique physical and chemical properties, this research aimed to study the capacity of Antarctic bacterial strains to produce cold-active β-galactosidases. A screening revealed 81 out of 304 strains with β-galactosidase activity. The strain Se8.10.12 showed the highest enzymatic activity. Morphological, biochemical, and molecular characterization based on whole-genome sequencing confirmed it as the first

Indexed as

Cold TemperatureAcclimatizationbeta-GalactosidaseEnzyme StabilityRahnellabeta-GalactosidaseAntarcticacold-adapted bacteriaextremozymeslactoseβ-galactosidase

Identifiers

PMID33923711
PMCPMC8074230
OpenAlexW3156112300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.